Genmab A/S

Major Shareholder Announcement

Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone

Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL

Articles of Association for Genmab A/S

Grant of Warrants to Genmab Employees

Genmab Announces Start of Rolling Submission of Biologics License Application for Daratumumab for Double Refractory Multiple Myeloma to the FDA

Genmab to Present at the Goldman Sachs 36th Annual Global Healthcare Conference

Genmab Gains License to Antibody Panel Targeting CD19

Ofatumumab Included in Regulatory Submission to US Authorities from Gilead

Genmab’s Total Number of Voting Rights and Total Share Capital

Articles of Association for Genmab A/S

Ofatumumab and Daratumumab Data to Be Presented at 20th Congress of EHA

Report Pursuant to Section 28a of the Danish Securities Trading Act

Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2015

Genmab Enters Commercial DuoBody® Technology Agreement with BioNTech in Field of Immuno-oncology

HuMax-TF-ADC and Daratumumab Data to Be Presented at 2015 ASCO Annual Meeting

Genmab Announces Financial Results for the First Quarter of 2015

First Quarter 2015 Net Sales Figures for Arzerra® (Ofatumumab)

Genmab Announces Phase III Study of Arzerra® Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL

Genmab Achieves USD 10 Million Milestone in Daratumumab Collaboration with Janssen

Articles of Association for Genmab A/S

Genmab’s Total Number of Voting Rights and Total Share Capital

Report Pursuant to Section 28a of the Danish Securities Trading Act

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to two Board Members and Grant of Warrants to Employees in Genmab

Passing of Genmab A/S’ Annual General Meeting

Genmab Acquires Antibody Assets from iDD Biotech

Genmab Retains Partial Rights for HuMax-TAC-ADC – Will Not Exercise Co-development Right

Articles of Association for Genmab A/S

Report Pursuant to Section 28a of the Danish Securities Trading Act

Report Pursuant to Section 28a of the Danish Securities Trading Act